A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies

Figure 14

Quantification of the ADCC activity of cetuximab using iLite Effector cells and EGFR⁺ or EGFR⁻ target cells. iLite effector cells V-variant (1.2 × 10⁵ cells/well) and/or EGFR⁺ or EGFR⁻ EK293 target in culture or RTU iLite effector cells and EGFR⁺ or EGFR⁻ HEK293 target cells were mixed at an E:T ratio of 4 : 1 and incubated for 6 hours at 37°C in the presence of increasing concentrations of cetuximab prior to the addition of Nano-Glo Dual-luciferase reagent (Promega, Madison, WI) and the sequential determination of FL and NL activity. (a) Cells in culture and (b) RTU cells.

(a) Cells in culture

(b) RTU frozen cells